Millendo Therapeutics, Inc.
MLND · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $28 | $20 | $28 | $14 |
| G&A Expenses | $14 | $16 | $18 | $12 |
| SG&A Expenses | $14 | $16 | $18 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $42 | $36 | $45 | $27 |
| Operating Income | $0 | -$36 | -$45 | -$27 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | $1 | -$0 |
| Pre-Tax Income | -$42 | -$36 | -$45 | -$27 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$42 | -$36 | -$45 | -$27 |
| % Margin | – | – | – | – |
| EPS | -1.5 | -28.95 | -48.77 | -263.65 |
| % Growth | 94.8% | 40.6% | 81.5% | – |
| EPS Diluted | -1.5 | -28.95 | -48.77 | -263.65 |
| Weighted Avg Shares Out | 28 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 28 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$1 | $0 | -$1 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $0 |
| EBITDA | $0 | -$35 | -$45 | -$27 |
| % Margin | – | – | – | – |